BIOTECH TARGET N V - 14 Nov 2024 Form 4 Insider Report for Molecular Templates, Inc. (MTEM)

Role
10%+ Owner
Signature
By: /s/Ivo Betschart
Issuer symbol
MTEM
Transactions as of
14 Nov 2024
Transactions value $
-$433,334
Form type
4
Filing time
18 Nov 2024, 21:12:24 UTC
Previous filing
04 Apr 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MTEM Common Stock Sale -$846K -1.28M -100% $0.66 0 14 Nov 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MTEM Prefunded Warrants (right to buy) Purchase $316K +135K $2.35 135K 02 Apr 2024 Common Stock 135K $0.00 Direct F1
transaction MTEM Common Warrants (right to buy) Purchase $96.2K +769K $0.13 769K 02 Apr 2024 Common Stock 769K $2.35 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

BIOTECH TARGET N V is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 The Common Warrants have a term of five years and the Prefunded Warrants will expire when fully exercised in accordance with their terms. The Prefunded and Common Warrants may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed 9.99% of the number of the shares of Common Stock outstanding immediately following such exercise.

Remarks:

Biotech Target N.V. is a wholly-owned subsidiary of BB Biotech AG. Accordingly, BB Biotech AG may be deemed to be the indirect beneficial owner of the securities of Molecular Templates, Inc. held directly or indirectly by Biotech Target N.V. This Form 4 is filed jointly by BB Biotech AG and Biotech Target N.V.